SB 537 revises Montana's marijuana tax revenue distribution, directing funds from the marijuana state special revenue account to new and existing state accounts. It requires transferring excess funds annually to specific accounts, including 12% to the HEART account for addiction treatment and mental health programs, 20% to wildlife habitat projects, and 14% to behavioral health initiatives. The bill also allocates funds for law enforcement canine training, sexual assault evidence kits, and homeless shelter support, while modifying existing transfer rules for agencies like the Department of Fish, Wildlife, and Parks. These changes apply to all state agencies receiving marijuana tax revenue under Montana law.
SB 504 proposes creating a $75 million grant program to fund permanent supportive housing projects in Montana. The bill would provide grants to nonprofit organizations for constructing, rehabilitating, or acquiring housing that offers long-term affordable leases (for residents earning 60% or less of the area median income) and onsite support services like mental health care, job assistance, and addiction recovery. It allocates $50 million from the general fund and $25 million from a behavioral health fund, with grants disbursed based on project proposals and adherence to specific conditions, including outcome tracking. The program, administered by the Montana Department of Commerce, aims to directly support homeless or at-risk individuals through housing and integrated services, effective July 1, 2025. (Note: The bill died in process in May 2025 and did not become law.)
HB 867 establishes a medical assistance program specifically for licensed chiropractors and veterinarians. This program provides support and monitors rehabilitation for these professionals who are impaired by substance abuse, mental illness, or chronic physical illness. To fund this initiative, the bill allows the respective boards to adjust the license renewal fees for chiropractors and veterinarians. It also updates existing laws concerning the confidentiality and auditing of professional medical assistance programs to include these new licensee groups.
This bill would have repealed a 2023 law (Section 7, Chapter 187) that was set to terminate Montana's chemical dependency treatment voucher program. It aimed to prevent the program's end by removing the termination provision, ensuring continued funding for individuals seeking substance use disorder treatment. The bill specified immediate effectiveness upon approval but did not become law. It died in the legislative process in May 2025, so the voucher program's termination date remains in effect as originally scheduled under the 2023 law.
HB 397 establishes confidentiality standards for mental health digital services. It defines these services as mobile applications or websites that collect, use, or access information related to an individual's mental health or substance use disorder, market themselves as facilitating such services, and use the information for diagnosis, treatment, or management. The bill subjects these services to existing health care information disclosure and confidentiality provisions. It also provides for enforcement and remedies for individuals whose information is disclosed in violation of these standards.
SB 503 allows for the use of expired opioid antagonists, such as naloxone, to treat opioid-related drug overdoses. This bill grants partial immunity from liability to school employees, eligible recipients, medical practitioners, and pharmacists who administer or distribute these expired medications in good faith. It amends existing law to explicitly permit schools to stock and use expired opioid antagonists and extends immunity to school personnel, except in cases of gross negligence or intentional misconduct. The bill's purpose is to broaden access to life-saving opioid antagonist medication by permitting the use of expired doses.
HB 50 protects parents and pregnant women with drug use disorder by preventing child welfare investigations or custody actions solely based on positive drug test results. It amends Montana law to shield individuals seeking treatment or prenatal care from criminal charges related to drug use, and prohibits using drug test results alone to initiate child abuse cases or remove children from homes. The bill directly affects pregnant women, parents, healthcare providers, and child welfare systems by ensuring medical care access isn't penalized. Key provisions include immunity for seeking overdose help and requiring medical evaluation as the primary factor in child welfare decisions.
HB 774 would require Montana Medicaid and commercial health insurance plans to provide equal coverage for FDA-approved nonopioid pain medications compared to opioid medications. The bill prohibits insurers from disadvantaging nonopioid drugs through formulary placement (like higher cost-sharing tiers) or more restrictive prior authorization requirements than for opioids. It also mandates that healthcare providers can request exceptions to coverage restrictions for nonopioid drugs when they determine such drugs are appropriate for a patient. This law aims to ensure patients have full access to pain management options without insurance barriers.
SB 446 revises laws related to health utilization review, affecting health insurance companies, utilization review organizations, and patients. It requires that only a physician licensed in the state, with a relevant specialty, can make adverse determinations (denials of coverage) or review grievances. The bill also restricts health insurance issuers from requiring prior authorization for certain prescription drugs, such as some generics, drugs for substance use disorder, and long-acting injectable antipsychotics. If an issuer or utilization review organization fails to comply with the requirements, the healthcare service under review will be automatically approved.
